0000000000066868

AUTHOR

Adriane Peveling-oberhag

showing 15 related works from this author

Development and validation of the mastocytosis quality of life questionnaire: MC-QoL

2016

Background Mastocytosis is a heterogeneous disease characterized by a clonal expansion of mast cells in various organs. The vast majority of patients affected suffer from signs and symptoms caused by mediator release from mast cells. Although the disease burden is high, there is currently no specific instrument to measure health-related quality of life (HRQoL) impairment in patients with mastocytosis. Objective The aim of this study was to develop and validate a disease-specific tool to assess HRQoL impairment in patients with cutaneous and indolent systemic mastocytosis, the Mastocytosis Quality of Life Questionnaire (MC-QoL). Methods Sixty-two potential MC-QoL items were developed in a co…

AdultMalemedicine.medical_specialtyPathologyAdolescentImmunologyDiseaseMediator releaseYoung Adult030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeSurveys and QuestionnairesInternal medicinemedicineHumansImmunology and AllergyIn patientSystemic mastocytosisDisease burdenAgedFace validityAged 80 and overbusiness.industryReproducibility of ResultsMiddle Agedmedicine.diseasehumanitiesCombined approach030228 respiratory systemPopulation SurveillanceQuality of LifeFemaleFactor Analysis StatisticalbusinessMastocytosisAllergy
researchProduct

The Urticaria Activity Score-Validity, Reliability, and Responsiveness.

2018

Background Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. Objective To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC). Methods One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatG…

AdultMalemedicine.medical_specialtyUrticariaIntraclass correlationOmalizumabOmalizumabSeverity of Illness IndexDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesInternal medicineAnti-Allergic AgentsImmunology and AllergyMedicineHumansskin and connective tissue diseasesReceiver operating characteristicbusiness.industryReproducibility of ResultsDermatology Life Quality IndexMiddle AgedStandard error030228 respiratory systemChronic DiseasePhysical therapyPatient-reported outcomeFemalebusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab

2018

Urticariabusiness.industryImmunologyUrticària -- TractamentTotal igeOmalizumabOmalizumabImmunoglobulin E030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineText mining030228 respiratory systemAnti-Allergic AgentsChronic DiseaseImmunologyHumansImmunology and AllergyMedicineDrug Monitoringbusinessmedicine.drug
researchProduct

A Popular myth - low-histamine diet improves chronic spontaneous urticaria - fact or fiction?

2016

Background Chronic spontaneous urticaria (CsU) is a frequent dermatological disease that might last for months or years with high impact on quality of life. Known causes are autoreactive phenomena, infections or intolerances, rarely IgE-mediated allergies. One third of CsU patients benefit from a low-pseudoallergen diet. Additionally, it is often discussed, that reducing histamine ingestion alone might improve clinical symptoms and quality of life in CsU-patients despite the uncertain role of the histamine-degrading enzyme diamine oxidase (DAO). Objective Aim of this study is to investigate the impact of low-histamine diet on symptoms and quality of life in patients with CsU. Methods Patien…

Malemedicine.medical_specialtyAllergyUrticariaDermatologySeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineIntolerancesQuality of lifeSurveys and QuestionnairesElimination dietInternal medicineSeverity of illnessmedicineClinical endpointHumansIngestionbusiness.industrymedicine.diseaseSurgeryTreatment OutcomeInfectious Diseases030228 respiratory systemChronic DiseaseQuality of LifeFemaleAmine Oxidase (Copper-Containing)Diamine oxidasebusinessHistamineJournal of the European Academy of Dermatology and Venereology
researchProduct

Extemporaneous formulations in Germany – relevance for everyday clinical practice

2017

Background Extemporaneous formulations broaden the spectrum of therapeutic options for topical treatment in particular and thus improve patient care. The latest amendment to the Regulation on the Operation of Pharmacies issued in 2012 brought about changes in prescribing and manufacturing practices. The aim of the present study was to assess the relevance of extemporaneous formulations in everyday clinical practice. Methods We used data from the German Institute for Drug Use Evaluation (DAPI) to analyze the prescribing practice for compounded preparations in Germany between the fourth quarter of 2011 and the third quarter of 2014. In doing so, we determined the total cost associated with ex…

Pharmaciesmedicine.medical_specialtybusiness.industryAdministration TopicalDrug CompoundingPharmacyDermatologyClinical Practice030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineAmbulatory careGermany030220 oncology & carcinogenesisFamily medicineHealth careHealth insuranceHumansRelevance (law)MedicineMedical prescriptionbusinessDrug use evaluationJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults:HAE-QoL

2016

Background: Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) may affect health-related quality of life (HRQoL). A specific HRQoL questionnaire for adult patients with C1-INH-HAE, the HAE-QoL, has recently been developed in Spain. Objective: The objective of this study was to perform a cross-cultural validation and psychometric study of the HAE-QoL in an international setting. Methods: Cross-cultural adaptation of the Spanish HAE-QoL draft version and an international rating phase with experts were performed. The resultant version of the HAE-QoL, a clinical questionnaire, and Short Form 36-item Health Survey Version 2.0 (SF-36v2) were pilot tested internationally. Item reduc…

AdultMaleQuality of lifemedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDPsychometricsPsychometricsIntraclass correlationMedicina ClínicaSF-36v203 medical and health sciences0302 clinical medicineCronbach's alphaSurveys and QuestionnairesmedicineHumansImmunology and AllergyAdults030212 general & internal medicineAlergiasHAE-QoLPsychiatryDisease-specificHereditary angioedemaC1 inhibitorbusiness.industryQuestionnaireAngioedemas Hereditarymedicine.diseaseMental healthhumanitiesExploratory factor analysis030228 respiratory systemConvergent validityValidation studiesItem reductionHereditary angioedemaQuality of LifeFemalebusinessPsychometric
researchProduct

High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema.

2015

<b><i>Background/Aims:</i></b> According to current guidelines, the emergency kit for patients with severe urticaria and/or angioedema should include a corticosteroid with a prednisolone-equivalent of 50-100 mg. Since severe dysphagia may occur in anaphylaxis, liquid corticosteroids are advantageous. Presently, only liquid preparations with less than 100 mg prednisolone equivalent are available worldwide. <b><i>Methods:</i></b> We prepared a highly concentrated liquid prednisolone formula for oral administration (1 or 5 mg prednisolone per ml). We observed efficacy and safety of 100 mg or >250 mg liquid oral prednisolone in comparison to in…

AdultMaleAdolescentUrticariaPhysiologymedicine.drug_classmedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsAdministration OralDermatologyDosage form030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineOral administrationmedicineHumansAngioedemaAgedPharmacologyHigh concentrationDosage FormsAngioedemabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemIntravenous therapyAnesthesiaPrednisoloneCorticosteroidFemalemedicine.symptombusinessAnaphylaxismedicine.drugSkin pharmacology and physiology
researchProduct

Severe chronic spontaneous urticaria in children – treatment options according to the guidelines and beyond – a 10 years review

2020

This is a retrospective study of 18 children with chronic spontaneous urticaria (CSU), where standard therapies, including up-dosing of antihistamines and omalizumab, were unable to cure the disease and where alternative strategies with experimental and off-label medication had to be used. Being aware that our questionnaire is validated only for elder children or adults, we utilized the UAS7 to monitor disease control with the help of the parents. The UAS7 score decreased from a mean of 25 to an average of 13 after 8 weeks of therapy in 13 patients. Five patients had no significant reduction of UAS7 by week 8. In two of five patients, where periodic improvement was seen, omalizumab therapy …

AdultPediatricsmedicine.medical_specialtyUrticariaDermatologyOmalizumabOmalizumab030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseasesAnti-Allergic AgentsmedicineHumansChronic Urticariaskin and connective tissue diseasesChildAgedRetrospective Studies030203 arthritis & rheumatologybusiness.industryTreatment optionsRetrospective cohort studyDupilumabhumanitiesbody regionsTreatment OutcomeChronic Diseasebusinessmedicine.drug
researchProduct

Epidemiology of urticaria in German children

2020

Background To date, robust epidemiological metrics as well as data on comorbidity in pediatric urticaria are lacking. They form the basis for the design of efficient healthcare. Methods Retrospective study to analyze epidemiological data in pediatric urticaria. The analysis is based on routine data of a health insurance company operating throughout Germany (DAK-Gesundheit). Insured people under 18 years of age who received at least one confirmed outpatient or inpatient urticaria diagnosis according to the ICD-10 classification in the years 2010 to 2015 were included in the analysis and compared to children without a corresponding diagnosis. Results Of 2.3 million insured individuals, 313,58…

Malemedicine.medical_specialtyPediatricsAdolescentUrticaria610 MedizinMEDLINEComorbidityDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseases610 Medical sciencesHealth careEpidemiologyPrevalenceHealth insuranceHumansMedicineChildskin and connective tissue diseasesRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseComorbidityObesityMental healthFemalebusinessDelivery of Health CareJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

High prevalence and little awareness in patients with chronic inflammatory skin diseases and genital involvement.

2020

Background Genital involvement in patients with chronic inflammatory skin diseases is frequent, yet insufficiently acknowledged. Objective To evaluate the prevalence of genital symptoms in psoriasis and chronic urticaria patients, effects on quality of life, physician-patient relations and disease management. Patients and methods 100 patients with psoriasis and 100 with chronic urticaria from our outpatient clinic, as well as 50 healthy controls were included. Data was collected using questionnaires developed by dermatological experts. Results Out of 250 subjects, 74 % had already experienced genital symptoms - 70 % of psoriasis patients and 58 % of urticaria patients. Seven out of ten even…

medicine.medical_specialtyHigh prevalenceUrticariabusiness.industry610 MedizinDermatologymedicine.diseaseDermatologyQuality of lifePsoriasis610 Medical sciencesChronic DiseasemedicinePrevalenceQuality of LifeOutpatient clinicHumansPsoriasisSex organIn patientGenitaliaDisease management (health)skin and connective tissue diseasesbusinessChronic urticariaJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Dermatologische Rezepturen in Deutschland - Relevanz für die Versorgung.

2017

030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinebusiness.industry030220 oncology & carcinogenesisMedicineLibrary scienceDermatologybusinessJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.

2016

AdultMalemedicine.medical_specialtyUrticariaImmunologyTreatment outcomePlacebo-controlled studyMEDLINEDrug ResistanceHistamine AntagonistsOmalizumabOmalizumablaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicineAnti-Allergic AgentsImmunology and AllergyMedicineHumansbusiness.industryMiddle AgedSymptomatic dermographismTreatment Outcome030228 respiratory systemMulticenter studyFemalebusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Comparison and interpretability of the available urticaria activity scores

2017

The urticaria activity score (UAS) is the gold standard for assessing disease activity in patients with chronic spontaneous urticaria (CSU). Two different versions, the UAS7 and UAS7TD , are currently used in clinical trials and routine care. To compare both versions and to obtain data on their interpretability, 130 CSU patients applied both versions and globally rated their disease activity as none, mild, moderate, or severe. UAS7 and UAS7TD values correlated strongly (r = .90, P < .001). Interquartile ranges for UAS7 and UAS7TD values for mild, moderate, and severe CSU were 11-20 and 10-24, 16-30 and 16-32, and 27-37 and 28-40. UAS7 values were slightly, but significantly lower as compare…

AdultMalemedicine.medical_specialtyUrticariaImmunologySeverity of Illness IndexMean differenceDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineOutcome Assessment Health CaremedicineHumansImmunology and AllergyIn patientRoutine careInterpretabilitybusiness.industryReproducibility of ResultsGold standard (test)Middle AgedSurgeryClinical trial030228 respiratory systemFemalebusinessBiomarkersAllergy
researchProduct

The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference

2016

Background The Angioedema Quality of Life Questionnaire (AE-QoL) has recently been developed and validated as the first specific patient-reported outcome tool to assess quality of life (QoL) impairment in recurrent angioedema patients. As of yet, its sensitivity to change and minimal clinically important difference (MCID) have not been established. Methods Recurrent angioedema patients with chronic spontaneous urticaria or hereditary angioedema were repeatedly asked to complete the AE-QoL along with the SF-12 and other anchors for QoL impairment and disease activity during routine care visits. The sensitivity to change of AE-QoL was determined by correlating changes in its scores over time …

AdultMalemedicine.medical_specialtyUrticariaClinical immunologyImmunologyMinimal Clinically Important DifferenceDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeRecurrenceSurveys and QuestionnairesHumansImmunology and AllergyMedicineAngioedemaSensitivity to changeskin and connective tissue diseasesRoutine careAngioedemabusiness.industryMinimal clinically important differenceReproducibility of ResultsMiddle Agedmedicine.diseasehumanities030228 respiratory systemChronic DiseaseHereditary angioedemaQuality of LifePhysical therapyFemalesense organsmedicine.symptombusinessAllergy
researchProduct

Responsiveness and minimal important difference of the urticaria control test

2017

This study demonstrates the responsiveness of the Urticaria Control Test (UCT). Changes of its score by 3 points or more reflect a clinically relevant change of disease control (minimal important difference).

medicine.medical_specialtybusiness.industryImmunologyTreatment outcomeOmalizumabDisease controlDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChronic disease030228 respiratory systemQuality of lifeControl testInternal medicineSeverity of illnessmedicinePhysical therapyImmunology and Allergysense organsskin and connective tissue diseasesbusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct